<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="73896">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01946243</url>
  </required_header>
  <id_info>
    <org_study_id>18F-AV-45-QP01</org_study_id>
    <nct_id>NCT01946243</nct_id>
  </id_info>
  <brief_title>The Feasibility of Florbetapir Quantitation</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avid Radiopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avid Radiopharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of the study is to assess the feasibility of implementing a
      quantitative process of florbetapir F 18 scan interpretation. The hypothesis is that the use
      of quantitative analysis will increase the accuracy of florbetapir F 18 scan interpretation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Change in reader accuracy after application of quantitation software</measure>
    <time_frame>Scan acquired 50-60 min post injection</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate whether the use of quantitation software improves the total accuracy of florbetapir F 18 scan interpretation. Total accuracy is defined as the number of scans correctly interpreted (vs. a truth standard) divided by the total number of scans read.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in scan interpretation reliability after application of quantitation software</measure>
    <time_frame>Scan acquired 50-60 min post injection</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate whether the use of quantitation software improves the reliability of florbetapir F 18 scan interpretation. The scan interpretation reliability will be evaluated using Fleiss' Kappa statistics.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Alzheimers Disease</condition>
  <arm_group>
    <arm_group_label>Physician Readers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Physician readers will interpret Amyvid scans using qualitative analysis followed by the use of quantitation. No subjects will be exposed to Florbetapir F 18 as part of this study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Florbetapir F18</intervention_name>
    <description>No Florbetapir F 18 will be administered in this study.</description>
    <arm_group_label>Physician Readers</arm_group_label>
    <other_name>Amyvid</other_name>
    <other_name>18F-AV-45</other_name>
    <other_name>florbetapir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Readers have undergone Amyvid reader training

          -  Readers have minimal experience with quantitation of amyloid PET scans

        Exclusion Criteria:

          -  Readers have previously been trained to quantitate amyloid PET scans
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Director</role>
    <affiliation>Avid Radiopharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Avid Clinical Operations</last_name>
    <phone>215-298-0700</phone>
    <email>clinicaloperations@avidrp.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 21, 2013</lastchanged_date>
  <firstreceived_date>September 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
